N. Foot

发表

3′ CBFβ deletion associated with inv(16) in acute myeloid leukemia

M. Neat, M. Humphreys, H. Enright, 2005 .

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

C. Crawley, D. Marin, J. Goldman, 2003, Leukemia.

Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa

J. Klein, D. Marin, J. Goldman, 2003, The Lancet.

Novel mutations and polymorphisms in the Fanconi anemia group C gene

C. Mathew, T. de Ravel, R. Gibson, 1996, Human mutation.

Expression profile of wild‐type ETV6 in childhood acute leukaemia

K. Pritchard-Jones, V. Saha, A. Ford, 2003, British journal of haematology.

Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate.

D. Marin, J. Goldman, M. Bua, 2003, Haematologica.

Detection of cryptic and variant IGH-MYC rearrangements in high-grade non-Hodgkin's lymphoma by fluorescence in situ hybridization: implications for cytogenetic testing.

M. Neat, N. Foot, Philippa C. May, 2010, Cancer genetics and cytogenetics.

Genetic susceptibility to Hodgkin's disease and secondary neoplasias: FISH analysis reveals patients at high risk of developing secondary neoplasia.

T. Lister, A. Rohatiner, M. Neat, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma.

T. Lister, A. Rohatiner, M. Neat, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transformation from follicular lymphoma to biphasic high-grade large B-cell lymphoma with immunophenotypically and genetically distinct diffuse large B cell and Burkitt-like components

M. Neat, B. Wilkins, N. Foot, 2013, Journal of Clinical Pathology.

Localisation of a novel region of recurrent amplification in follicular lymphoma to an approximately 6.8 Mb region of 13q32-33.

T. Lister, A. Norton, A. Dunham, 2001, Genes, chromosomes & cancer.

Teaching Cases from the Royal Marsden and St Mary's Hospitals Case 28: A Patient with Acute Leukemia with Rare Leukemic Cells of Unusual Morphology

B. Bain, D. Wrench, N. Foot, 2004, Leukemia & lymphoma.

Molecular MRD status and outcome after transplantation in NPM1 mutated AML: results from the UK NCRI AML17 study.

N. Potter, C. Craddock, R. Hills, 2019, Blood.

Bortezomib, doxorubicin and dexamethasone (PAD) front‐line treatment of multiple myeloma: updated results after long‐term follow‐up

D. Esseltine, J. Cavenagh, N. Curry, 2008, British journal of haematology.

Fluorescence in situ hybridisation analysis of bone marrow trephine biopsy specimens; an additional tool in the diagnostic armoury

M. Neat, N. Foot, M. Moonim, 2012, Journal of Clinical Pathology.

A role for mitotic recombination in leukemogenesis.

M. Raghavan, B. Young, D. Lillington, 2006, Advances in enzyme regulation.

The characterisation of the lymphoma cell line U937, using comparative genomic hybridisation and multi-plex FISH

R. Oliver, M. Neat, B. Young, 2001, Cytogenetic and Genome Research.

Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.

D. Marin, J. Goldman, M. Bua, 2003, Haematologica.

The most frequent constitutional translocation in humans, the t(11;22)(q23;q11) is due to a highly specific alu-mediated recombination.

B. Young, T. Chaplin, N. Foot, 2000, Human molecular genetics.

Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias.

T. Lister, M. Raghavan, B. Young, 2005, Cancer research.

Localisation of a novel region of recurrent amplification in follicular lymphoma to an ∼6.8 Mb region of 13q32‐33

A. Norton, A. Dunham, T. A. Lister, 2001 .

Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event.

Diana Blaydon, D. Kelsell, C. Proby, 2005, Cancer research.

ALK rearrangements in EBUS‐derived transbronchial needle aspiration cytology in lung cancer

E. Mclean, M. Neat, G. Santis, 2013, Cytopathology : official journal of the British Society for Clinical Cytology.

Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia

Zhiyuan Luo, Vaskar Saha, Tony Bellotti, 2005, British journal of haematology.

Fluorescence in situ hybridisation analysis of formalin-fixed paraffin-embedded tissue sections in the diagnostic work-up of non-Burkitt high grade B-cell non-Hodgkin's lymphoma: a single centre's experience

M. Neat, B. Wilkins, N. Foot, 2011, Journal of Clinical Pathology.

European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms

E. van den Berg, C. Haferlach, Z. Zemanová, 2019, Leukemia.

Bortezomib, low‐dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma

C. Craddock, J. Cavenagh, S. Joel, 2007, British journal of haematology.

European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms: reponse to the comments from the Francophone Group of Hematological Cytogenetics (GFCH)

E. van den Berg, C. Haferlach, Z. Zemanová, 2020, Leukemia.

M. Dyer, N. Potter, N. Russell, 2021, Leukemia.

Reduced Dose PAD Combination Therapy (PS-341/Bortezomib, Adriamycin and Dexamethasone) for Previously Untreated Patients with Multiple Myeloma.

D. Esseltine, J. Cavenagh, D. Schenkein, 2005 .

Pre-Transplant NPM1 Mutant Transcript Level Is Highly Predictive of Outcome after Allograft and Thresholds Are Dependent on FLT3 ITD Status

N. Potter, R. Hills, N. Russell, 2018, Blood.

A Phase I/II Study of Bortezomib and Low Dose Intravenous Melphalan (BM) for Relapsed Multiple Myeloma.

C. Craddock, J. Cavenagh, S. Basu, 2005 .

Autoimmune cytopenias in the 22q11.2 deletion syndrome.

J. Cavenagh, M. Neat, P. Telfer, 2003, Clinical and laboratory haematology.

Comparative genomic hybridization and multiplex-fluorescence in situ hybridization: an appraisal in elderly patients with acute myelogenous leukemia.

A. Rohatiner, M. Neat, B. Young, 2002, The hematology journal : the official journal of the European Haematology Association.

3'CBFbeta deletion associated with inv(16) in acute myeloid leukemia.

M. Neat, M. Humphreys, H. Enright, 2005, Cancer genetics and cytogenetics.

Long term follow-up of PAD for untreated multiple myeloma

D. Esseltine, J. Cavenagh, N. Curry, 2007 .